342 related articles for article (PubMed ID: 34075102)
21. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43.
Caccamo A; Shaw DM; Guarino F; Messina A; Walker AW; Oddo S
Hum Mol Genet; 2015 Aug; 24(16):4625-35. PubMed ID: 26002100
[TBL] [Abstract][Full Text] [Related]
22. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.
Mashiko T; Sakashita E; Kasashima K; Tominaga K; Kuroiwa K; Nozaki Y; Matsuura T; Hamamoto T; Endo H
J Biol Chem; 2016 Jul; 291(29):14996-5007. PubMed ID: 27226551
[TBL] [Abstract][Full Text] [Related]
23. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration.
Nishimura AL; Zupunski V; Troakes C; Kathe C; Fratta P; Howell M; Gallo JM; Hortobágyi T; Shaw CE; Rogelj B
Brain; 2010 Jun; 133(Pt 6):1763-71. PubMed ID: 20472655
[TBL] [Abstract][Full Text] [Related]
24. An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-κB signalling and is associated with reduced phosphorylation of p62.
Foster A; Scott D; Layfield R; Rea SL
Mol Cell Neurosci; 2019 Jul; 98():32-45. PubMed ID: 30954537
[TBL] [Abstract][Full Text] [Related]
25. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
[TBL] [Abstract][Full Text] [Related]
26. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway.
Deng Z; Lim J; Wang Q; Purtell K; Wu S; Palomo GM; Tan H; Manfredi G; Zhao Y; Peng J; Hu B; Chen S; Yue Z
Autophagy; 2020 May; 16(5):917-931. PubMed ID: 31362587
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43.
King A; Maekawa S; Bodi I; Troakes C; Al-Sarraj S
Neuropathology; 2011 Jun; 31(3):239-49. PubMed ID: 21118398
[TBL] [Abstract][Full Text] [Related]
28. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-183-5p regulates TAR DNA-binding protein 43 neurotoxicity via SQSTM1/p62 in amyotrophic lateral sclerosis.
Kim HC; Zhang Y; King PH; Lu L
J Neurochem; 2023 Mar; 164(5):643-657. PubMed ID: 36527420
[TBL] [Abstract][Full Text] [Related]
30. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.
Tamaki Y; Urushitani M
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293362
[TBL] [Abstract][Full Text] [Related]
31. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
[TBL] [Abstract][Full Text] [Related]
32. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
33. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
34. RNA-binding proteins with prion-like domains in ALS and FTLD-U.
Gitler AD; Shorter J
Prion; 2011; 5(3):179-87. PubMed ID: 21847013
[TBL] [Abstract][Full Text] [Related]
35. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.
Liachko NF; McMillan PJ; Strovas TJ; Loomis E; Greenup L; Murrell JR; Ghetti B; Raskind MA; Montine TJ; Bird TD; Leverenz JB; Kraemer BC
PLoS Genet; 2014 Dec; 10(12):e1004803. PubMed ID: 25473830
[TBL] [Abstract][Full Text] [Related]
36. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS.
Krug L; Chatterjee N; Borges-Monroy R; Hearn S; Liao WW; Morrill K; Prazak L; Rozhkov N; Theodorou D; Hammell M; Dubnau J
PLoS Genet; 2017 Mar; 13(3):e1006635. PubMed ID: 28301478
[TBL] [Abstract][Full Text] [Related]
37. In vivo analysis of aggregation propensity of low levels of mislocalized TDP-43 on cytopathological and behavioral phenotype of ALS/FTLD.
Wada H; Hikiami R; Kusui M; Minamiyama S; Asada-Utsugi M; Shodai A; Muramatsu SI; Morimura T; Urushitani M
Neurosci Res; 2023 Aug; 193():41-51. PubMed ID: 36804599
[TBL] [Abstract][Full Text] [Related]
38. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
[TBL] [Abstract][Full Text] [Related]
39. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
[TBL] [Abstract][Full Text] [Related]
40. Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant.
King A; Al-Sarraj S; Troakes C; Smith BN; Maekawa S; Iovino M; Spillantini MG; Shaw CE
Acta Neuropathol; 2013 Feb; 125(2):303-10. PubMed ID: 23053136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
